ArticleTheranostics2016
In Vivo Targeting of Metabolically Labeled Cancers with Ultra-Small Silica Nanoconjugates.
Article in Theranostics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Programmable nanomedicine via bioorthogonal molecular engineering.Nano convergence · 2026Review
- Recent advances in developing active targeting and multi-functional drug delivery systems via bioorthogonal chemistry.Signal transduction and targeted therapy · 2022Review
- Metabolic glycan labelling for cancer-targeted therapy.Nature chemistry · 2020Review
- Metabolic labeling and targeted modulation of dendritic cells.Nature materials · 2020Article
- Article
- Bio-orthogonal click-targeting nanocomposites for chemo-photothermal synergistic therapy in breast cancer.Theranostics · 2020Article
- Azido-galactose outperforms azido-mannose for metabolic labeling and targeting of hepatocellular carcinoma.Biomaterials science · 2019Article
- Therapeutic Applications of Pretargeting.Pharmaceutics · 2019Review
- T Cell Membrane Mimicking Nanoparticles with Bioorthogonal Targeting and Immune Recognition for Enhanced Photothermal Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2019Article
- Optimization and Stability of Cell-Polymer Hybrids Obtained by "Clicking" Synthetic Polymers to Metabolically Labeled Cell Surface Glycans.Biomacromolecules · 2019Article
- Tumor-penetrating Peptide Conjugated and Doxorubicin Loaded TTheranostics · 2018Article
- Nanostructure-Based Theranostic Systems.Theranostics · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Unnatural sugar-mediated metabolic labeling of cancer cells, coupled with efficient Click chemistry, has shown great potential for in vivo imaging and cancer targeting. Thus far, chemical labeling of cancer cells has been limited to the small-sized azido groups, with the large-sized and highly hydrophobic dibenzocyclooctyne (DBCO) being correspondingly used as the targeting ligand. However, surface modification of nanomedicines with DBCO groups often suffers from low ligand density, difficult functionalization, and impaired physiochemical properties. Here we report the development of DBCO-bearing unnatural sugars that could directly label LS174T colon cancer cells with DBCO groups and subsequently mediate cancer-targeted delivery of azido-modified silica nanoconjugates with easy functionalization and high azido density in vitro and in vivo. This study, for the first time, demonstrates the feasibility of metabolic labeling of cancer cells with large-sized DBCO groups for subsequent, efficient targeting of azido-modified nanomedicines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.